Left and right ventricular diastolic dysfunction in patients with early rheumatoid arthritis before prescribing disease-modifying antirheumatic therapy


Cite item

Full Text

Abstract

Aim. To estimate the rate of diastolic dysfunction (DD) of the left and right ventricles (LV and RV) in patients with early rheumatoid arthritis (RA) before using disease-modifying antirheumatic drugs (DMARDs) therapy and to investigate its association with traditional risk factors (TRFs) for cardiovascular diseases (CVD) and inflammatory markers. Subjects and methods. The investigation enrolled 74 patients with a valid diagnosis of RA, including 56 (74%) women (median age, 54 years; disease duration, 7 months); the patients who were seropositive for rheumatoid factor (RF) (87%) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies (100%) who had not been on DMARDs or glucocorticosteroids. TRFs for CVD and carotid artery atherosclerosis were assessed from duplex scanning data and echocardiography was performed in all the patients with early RA before starting the therapy. The ratio of the maximum blood flow velocity during early diastolic filling (E) to that during atrial systole (A) was used as a criterion for LVDD and RVDD. There were 3 types of impaired ventricular filling: 1) E/A <1; 2) E/A = 1—2; 3) E/A >2. Results. LVDD and RVDD were detected in 35 (48%) and 17 (23%) patients, respectively. RVDD was recorded only in conjunction with LVDD. Among LVDD and RVDD, the former was prevalent. All the patients with early RA were divided into 3 groups: 1) patients with LVDD and RVDD; 2) those with LVDD; 3) those without ventricular DD. All the three groups were matched for the level of DAS28, anti-CCP antibodies, and RF. The incidence of arterial hypertension, dyslipidemia, and abdominal obesity was higher in the patients of Groups 1 and 2 than in those of Group 3. There was a progressive decrease in high-density lipoprotein (HDL) cholesterol concentrations and increases in triglyceride (TG) levels and atherogenic index from Group 3 to Group 1, with the concentrations of total cholesterol and low-density lipoprotein cholesterol being similar in the 3 groups. Coronary heart disease was recorded more frequently in Group 2 than in Group 3. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) proved to be also significantly higher in the patients with DD than in those without DD. Correlations were found between LV E/A and ESR, CRP, HDL cholesterol, TG, RV E/A and ESR, DAS28, TG. Conclusion. The patients with early-stage RA were found to have high incidence rates of LVDD and RVDD, which is related to the high prevalence of CVD, the high spread of TRF for CVD, and the high activity of an inflammatory process.

References

  1. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн: Насонова Е.Л., Насоновой В.А., ред. Ревматология. Национальное руководство. ГЭОТАР-Медиа 2008:290-331.
  2. Avina-Zubieta J, Choi H, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690-1697.
  3. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-494.
  4. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-732.
  5. Peters MJ, Symmons DP, McCarey DW, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis. 2010;69:325-331.
  6. Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, Antonini-Canterin F, Di Salvo G, De Gennaro Colonna V, La Carrubba S, Carerj S, Turiel M. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev. 2009;8(4):281-286.
  7. Levendoglu F, Temizhan A, Ugurlu H, Ozdemir A, Yazici M. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int. 2004;24(3):141-146.
  8. Abdul Muizz AM, Mohd Shahrir MS, Sazliyana S, Oteh M, Shamsul AS, Hussein H. A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity. Int J Rheum Dis. 2011;14:18-30.
  9. Rexhepaj N, Bajraktari G, Berisha I, Beqiri A, Shatri F, Hima F, Elezi S, Ndrepepa G. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Int J Clin Pract. 2006;60(6):683-688.
  10. Garza-García C, Sánchez-Santillán R, Orea-Tejeda A, Castillo-Martínez L, Eduardo C, López-Campos JL, Keirns-Davis C. Risk factors for asymptomatic ventricular dysfunction in rheumatoid arthritis patients. ISRNCardiol. 2013;635439.
  11. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, Borgeson DD, Therneau TM, Rodeheffer RJ, Gabriel SE. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann RheumDis. 2010;69(9):1665-1670.
  12. Voelkel NF, Quaife RA, Leinwand LA. Right ventricular function and failure. Circulation. 2006;114:1883-1891.
  13. Yazici D, Tokay S, Aydin S, Toprak A, Inanc N, Khan SR, Fak AS, Direskeneli H. Echocardiographic evaluation of сardiac diastolic function in patients with rheumatoid arthritis: 5 years of follow-up. Clin Rheumatol. 2008;27:647-650.
  14. Горбунова Ю.Н., Новикова Д.С., Попкова Т.В., Маркелова Е.И., Корсакова Ю.О., Фомичева О.А., Колмакова Д.С., Лучихина Е.Л., Каратеев Д.Е., Смирнов А.В., Насонов Е.Л. Кардиоваскулярный риск у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии (предварительные данные исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4):381-386.
  15. Рекомендации по кардиоваскулярной профилактике. Комитет экспертов РКО. Кардиоваскулярная терапия и профилактика. 2011;10(6):Приложение 2.
  16. Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? JAm Coll Cardiol. 2009;54:625-627.
  17. Lang RM, Bierig RB, Devereux А, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology Recommendations for chamber quantification. Eur J Echocardiography. 2006;7:79-108.
  18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
  19. Функциональная диагностика в кардиологии: клиническая интерпретация: учебное пособие. Под ред. Васюка Ю.А. М.: Практическая медицина; 2009.
  20. Национальные рекомендации ОССН, РКО И РНМОТ по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная недостаточность. 2013;81(7):379-472.
  21. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE. The risk of congestive heart failure in rheumatoid arthritis. Arthritis Rheum. 2005;2:412-420.
  22. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, Therneau TM, Gabriel SE. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011;38:1601-1606.
  23. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. The increased risk of ventricular diastolic dysfunction and congestive heart failure in patients with rheumatoid arthritis is independent of the duration of the disease. SeminArthritis Rheum. 2005;35(2):132-133. doi: 10.1016/j.semarthrit.2005.05.003.
  24. Anderson KM, Odel PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
  25. Obradović-Tomasević B, Vujasinović-Stupar N, Tomasević R. The assesment of diastolic function in patients with rheumatoid arthritis. Med Pregl. 2009;62(11-12):522-528.
  26. Ajeganova S, Andersson ML, Hafstrom I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset. Arthr Care Res. 2013;65:78-87.
  27. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. NEngl J Med. 2002;347:305-313.
  28. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. J Am Med Assoc. 2002;288:1252-1259.
  29. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35:1628-1637.
  30. Arnlov J, Lind L, Zethelius B, Hales CN, Vessby B, Lithell H. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142:720-724.
  31. Колотова Г.Б. Особенности морфофункционального состояния и типы ремоделирования левых отделов сердца у пациентов с серопозитивным и серонегативным ревматоидным артритом. Ультразвуковая и функциональная диагностика. 2008;3:35-41.
  32. Беленков Ю.Н. Ремоделирование левого желудочка: комплексный подход. Сердечная недостаточность. 2002;3(4):161-163.
  33. Aslam F, Bandeali SJ, Khan NA. Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res (Hoboken). 2013;65(4):534-543.
  34. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
  35. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:640-644.
  36. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305-311.
  37. Красносельский М.Я., Братанова М.З., Полупан А.А., Цурко В.В. Тканевая допплерография миокарда в диагностике поражения миокарда у больных ревматоидным артритом. Кардиология. 2007;10(47):59-62. Krasnosel’ski M, Bratanova M, Polupan A, Tsurko V. Tissue dopplerography of the myocardium in diagnosis of myocardial involvement in patients with rheumatoid arthritis. Kardiologiia. 2007;10(47):59-62.
  38. Arnab B, Biswadip G, Arindam P. Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? J Cardiovasc Dis Res. 2013;4(2):102-106.
  39. Konstam MA, Udelson JE. Right heart failure. In: Hosenpud JD, Greenberg ВР, eds. Congestive heart failure: pathophysiology, diagnosis, and comprehensive approach to management. 3nd ed. Lippincott Williams & Wilkins; 2006:361-382.
  40. Setaro JF, Cleman MW, Remetz MS. The right ventricle in disorders causing pulmonary venous hypertension. Cardiol Clin. 1992;10:165-183.
  41. Klima UP, Guerrero JL, Vlahakes GJ. Myocardial perfusion and right ventricular function. Ann Thorac Cardiovasc Surg. 1999;5:74-80.
  42. Polak JF, Holman L, Wynne J, Colucci WS. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol. 1983;2:217-224.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies